- Home
- ADIL vs ENSC Comparison
ADIL vs ENSC Comparison
Compare ADIL & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- ENSC
- Stock Information
- Founded
- ADIL 2010
- ENSC 2003
- Country
- ADIL United States
- ENSC United States
- Employees
- ADIL N/A
- ENSC N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- ADIL Health Care
- ENSC Health Care
- Exchange
- ADIL Nasdaq
- ENSC Nasdaq
- Market Cap
- ADIL 7.6M
- ENSC 6.4M
- IPO Year
- ADIL 2018
- ENSC N/A
- Fundamental
- Price
- ADIL $0.35
- ENSC $2.10
- Analyst Decision
- ADIL Strong Buy
- ENSC
- Analyst Count
- ADIL 1
- ENSC 0
- Target Price
- ADIL $8.00
- ENSC N/A
- AVG Volume (30 Days)
- ADIL 562.1K
- ENSC 54.6K
- Earning Date
- ADIL 11-12-2025
- ENSC 11-11-2025
- Dividend Yield
- ADIL N/A
- ENSC N/A
- EPS Growth
- ADIL N/A
- ENSC N/A
- EPS
- ADIL N/A
- ENSC N/A
- Revenue
- ADIL N/A
- ENSC $7,413,722.00
- Revenue This Year
- ADIL N/A
- ENSC N/A
- Revenue Next Year
- ADIL N/A
- ENSC $1,354.55
- P/E Ratio
- ADIL N/A
- ENSC N/A
- Revenue Growth
- ADIL N/A
- ENSC 415.58
- 52 Week Low
- ADIL $0.22
- ENSC $1.62
- 52 Week High
- ADIL $1.30
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- ADIL 36.98
- ENSC 48.61
- Support Level
- ADIL $0.36
- ENSC $2.02
- Resistance Level
- ADIL $0.38
- ENSC $2.19
- Average True Range (ATR)
- ADIL 0.02
- ENSC 0.10
- MACD
- ADIL 0.00
- ENSC 0.00
- Stochastic Oscillator
- ADIL 14.00
- ENSC 41.45
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.